Source: Annual Congress 2009 - Ventilator-associated pneumonia, severe community-acquired pneumonia and healthcare associated pneumonia
Disease area: Respiratory critical care, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
R. Seligman, J. Papassotiriou, N. Morgenthaler, M. Meisner, P. Teixeira, B. Seligman, S. Kretzer, V. Martins, L. F. Lima, V. Oliveira, C. Sanvicente, E. Pacheco, J. Sartori, K. Dalla Rosa, L. Restelatto (Porto Alegre, Brazil; Berlin, Dresden, Germany). MR-proANP and prognosis of ventilator-associated pneumonia. Eur Respir J 2009; 34: Suppl. 53, 2388

Member's Comments

No comment yet.

Related content which might interest you: Copeptin and prognosis of ventilator-associated pneumonia Source: Annual Congress 2008 - Features of hospital-acquired pneumonia, ventilator-associated pneumonia and infection with other pathogens Year: 2008 Predictive value of procalcitonin in ventilator-associated pneumonia Source: Annual Congress 2007 - Diagnostic markers and therapy in hospital-acquired pneumonia Year: 2007 Prognostic power of proadrenomedullin in community-acquired pneumonia is independent of aetiology Source: Eur Respir J 2012; 39: 1144-1155 Year: 2012 Specific treatment failure of the ventilator-associated pneumonia (VAP): predictive values Source: Eur Respir J 2006; 28: Suppl. 50, 786s Year: 2006 Is ventilated hospital-acquired pneumonia a worse entity than ventilator-associated pneumonia? Source: Eur Respir Rev, 29 (157) 200023; 10.1183/16000617.0023-2020 Year: 2020 Serum procalcitonin (PCT) as a marker of the severity and prognosis of ventilator-associated pneumonia (VAP) Source: Annual Congress 2007 - Diagnostic markers and therapy in hospital-acquired pneumonia Year: 2007 Diagnosis of ventilator-associated pneumonia Source: Annual Congress 2007 - Pulmonary infections and inflammation Year: 2007 Procalcitonin and D-dimer to predict prognosis and clinical outcomes in severe community-acquired pneumonia (SCAP) patients Source: Annual Congress 2012 - Respiratory infections: a clinical point of view Year: 2012 Thrombocytosis is a marker of poor outcome in community-acquired pneumonia Source: Annual Congress 2012 - Respiratory infections: prognosis and outcome Year: 2012 Prediction of prognosis in healthcare-associated pneumonia Source: Annual Congress 2012 - Respiratory infections: prognosis and outcome Year: 2012 The impact of inflammatory-response in the outcome of trauma patients with and without ventilator-associated pneumonia Source: Eur Respir J 2004; 24: Suppl. 48, 232s Year: 2004 Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study Source: Eur Respir J 2009; 34: 1364-1375 Year: 2009 Pro-atrial natriuretic peptide and pro-vasopressin to predict severity and prognosis in community-acquired pneumonia Source: Eur Respir J 2007; 30: Suppl. 51, 481s Year: 2007 How to prevent ventilator-associated pneumonia Source: Annual Congress 2013 –PG3 Infections and critical patients: emerging problems and clinical strategies Year: 2013 Sequential measurements of procalcitonin levels in diagnosing ventilator-associated pneumonia Source: Eur Respir J 2008; 31: 356-362 Year: 2008 Hospital-acquired and ventilator-associated pneumonia Source: ERS Courses: Paediatric respiratory infections Year: 2019 C-reactive protein and procalcitonin as predictors of survival and septic shock in ventilator-associated pneumonia Source: Eur Respir J 2010; 35: 805-811 Year: 2010 Value of bacteraemia as an unfavourable prognostic factor for community-acquired pneumonia Source: Eur Respir J 2006; 28: Suppl. 50, 350s Year: 2006